Non-tech summaries 2016: projects on nervous/mental disorders
Projects granted during 2016 that have a primary purpose of translational applied research - human nervous and mental disorders.
Documents
Details
This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2016 with a primary purpose of translational applied research - human nervous and mental disorders.
The following projects were granted:
-
developing therapies for perinatal diseases (lack of oxygen, brain haemorrhage)
-
neurovascular function in health and disease (brain, blood vessels, alzheimer’s disease, energy, pericyte)
-
assessment of blood brain barrier transporters (drug discovery; blood brain barrier)
-
modulating autophagy tct tackle huntington’s disease (autophagy, cell death, huntington’s disease)
-
translational pharmacology for drug discovery (pharmacology, drug, discovery)
-
electrophysiological studies of neurodegenerative disorders (neurodegeneration, drug discovery, electrophysiology, in vivo)
-
anaesthesia and the developing brain (anaesthesia, neurodegeneration, neuro-apoptosis, developing brain)
-
gene transcription events mediating brain and behaviour (epigenetics; post-transcriptional modification; imprinted genes; behaviour; brain)
-
examining the role of mitochondria in neurodegeneration and vascular disorders (alzheimers, blood vessels, mitochondria, neurodegeneration)
-
using zebrafish to understand disease and develop therapies (zebrafish, development, disability, therapy, mechanism)
-
pharmacodynamics and pharmacokinetics of novel compounds (drug discovery, receptor, pharmacokinetic, pharmacodynamic)
-
MK2 as a regulator of inflammation in alzheimer’s (alzheimer’s, inflammation, hippocampus, synaptic plasticity, behaviour.)
-
neural signalling and disease in rodents (motoneurone, mechanosensation, MND, hypertension)
-
repair in neurodegenerative disease and injury (central nervous system, nerve cells, neurodegenerative diseases, regeneration)
-
role of D1R-D3R heteromers in l-DOPA-induced dyskinesias (parkinson’s disease, dyskinesia, dopamine, heteromers, glutamate receptors)
-
maintenance and regeneration of the nervous system (avulsion, neurodegeneration)
-
determination of CNS efficacy and safety pharmacology (central nervous system, behaviour, safety)
-
zebrafish and medaka as models for the study of psychiatric disease and age-related cognitive decline (zebrafish, behaviour, addiction, genetic modification, ageing)
-
early life exposure to drugs and environmental complexity and neuropsychiatric disorder (genetics, nature/nurture, environmental complexity)
-
neurological disorders: mechanisms and therapies (behaviour, cognition, brain, neurological disorder)
-
analgesic potential of retargeted SNARE proteases (analgesia, pain, neuropathic, post-operative, inflammatory)
-
CNS neurotransmitter action in health and disease (brain, neurodevelopmental disorders, neurodegeneration, neuron, glia)
-
improving the treatment of parkinson’s disease and parkinson’s disease dementia (parkinson’s disease, dementia, better treatments, cell protection, cell repair)
-
neuropharmacology and therapeutics in addiction and other dopamine-associated disorders (addiction, parkinson’s disease, treatments, neurogenesis)